{"id":"NCT00772382","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia","officialTitle":"A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2010-08","completion":"2010-08","firstPosted":"2008-10-15","resultsPosted":"2014-05-12","lastUpdate":"2014-09-15"},"enrollment":116,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease","Dialysis","Hyperphosphatemia"],"interventions":[{"type":"DRUG","name":"MCI-196","otherNames":["Colestilan(INN)","Colestimide(JAN)","CHOLEBINE®","BindRen®"]}],"arms":[{"label":"MCI-196","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia.\n\nThe secondary objective of this study is to assess the long-term efficacy of flexible doses of MCI-196.","primaryOutcome":{"measure":"Number of Adverse Events (AE)","timeFrame":"52 weeks","effectByArm":[{"arm":"MCI-196","deltaMin":109,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":21,"countries":["United States","Canada"]},"refs":{"pmids":["26670307"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":63,"n":116},"commonTop":["Nausea","Vomiting","Diarrhoea","Decreased appetite","Haemodialysis-induced symptom"]}}